MIR1290, microRNA 1290, 100302276

N. diseases: 62; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.090 AlteredExpression group BEFREE We identified a downregulation of miR-1290 in ER(high) Ki67(low) tumors. 23183268 2013
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.020 Biomarker disease BEFREE miR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer. 23183268 2013
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.020 Biomarker disease BEFREE The detection of elevated circulating miR-1290 has the potential to improve the early detection of pancreatic cancer. 23697990 2013
CUI: C0346647
Disease: Malignant neoplasm of pancreas
Malignant neoplasm of pancreas 		0.020 Biomarker disease BEFREE The detection of elevated circulating miR-1290 has the potential to improve the early detection of pancreatic cancer. 23697990 2013
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.020 Biomarker disease BEFREE miR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer. 23183268 2013
CUI: C0206754
Disease: Neuroendocrine Tumors
Neuroendocrine Tumors 		0.010 Biomarker group BEFREE Of the significantly elevated circulating miRNAs in patients with pancreatic cancer compared with controls, miR-1290 had the best diagnostic performance: receiver operating characteristic (ROC) analysis on miR-1290 serum level yielded curve areas (AUC) of 0.96 [95% confidence interval (CI), 0.91-1.00], 0.81 (0.71-0.91), and 0.80 (0.67-0.93), for subjects with pancreatic cancer (n = 41) relative to healthy controls (n = 19), subjects with chronic pancreatitis (n = 35), and pancreatic neuroendocrine tumors (n = 18), respectively. 23697990 2013
CUI: C0280222
Disease: stage, pancreatic cancer
stage, pancreatic cancer 		0.010 AlteredExpression phenotype BEFREE Serum miR-1290 levels distinguished patients with low-stage pancreatic cancer from controls better than CA19-9 levels, and like CA19-9, higher miR-1290 levels predicted poorer outcome among patients undergoing pancreaticoduodenectomy. 23697990 2013
CUI: C2938924
Disease: Oestrogen receptor positive breast cancer
Oestrogen receptor positive breast cancer 		0.010 Biomarker disease BEFREE Our results suggest that miR-1290 and its potential targets might be associated with characteristics of ER-positive breast cancer. 23183268 2013
CUI: C3160815
Disease: Intraductal papillary mucinous neoplasm
Intraductal papillary mucinous neoplasm 		0.010 AlteredExpression disease BEFREE Serum miR-1290 levels were also significantly higher than healthy controls among patients with intraductal papillary mucinous neoplasm (IPMN; n = 20; AUC = 0.76, 0.61-0.91). 23697990 2013
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.020 Biomarker disease BEFREE The aim of the present study was to determine whether NAT1 is a bona fide target of miR-1290, and to investigate the impact of NAT1 on breast cancer prognosis. 25528056 2014
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.020 Biomarker disease BEFREE The aim of the present study was to determine whether NAT1 is a bona fide target of miR-1290, and to investigate the impact of NAT1 on breast cancer prognosis. 25528056 2014
CUI: C0018553
Disease: Hamartoma Syndrome, Multiple
Hamartoma Syndrome, Multiple 		0.010 Biomarker disease BEFREE Deregulation of seven miRNAs (miR-31-5p, miR-192-3p, miR-194-5p, miR-551a, miR-551b-5p, miR-638 and miR-1290) was determined in a larger series of CD patients with different clinical phenotypes compared with non-CD subjects. 24063611 2014
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.090 Biomarker group BEFREE Taken together, our findings suggested that miR-1290 functions as a tumor oncogene in the progression of ESCC by targeting NFIX. 26653554 2015
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.090 AlteredExpression group BEFREE Upregulation of miR-1290 was associated with tumor differentiation (P = 0.021), N classification (P = 0.006) and tumor-node-metastasis stage (P = 0.021) in ESCC patients. 25805931 2015
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.090 AlteredExpression phenotype BEFREE Moreover, ectopic miR-1290 expression potently promoted ESCC cell growth (P < 0.01), migration (P < 0.01) and invasion (P < 0.01) in vitro. miR-1290 overexpression in ESCC cell lines decreased SCAI expression at the translational level and reduced SCAI-driven luciferase-reporter activity (P < 0.01). 25805931 2015
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.090 Biomarker phenotype BEFREE We demonstrated that miR-1290 could promote proliferation, migration and invasion via the negative regulation of NFIX expression. 26653554 2015
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.070 Biomarker phenotype BEFREE MicroRNA-1290 promotes esophageal squamous cell carcinoma cell proliferation and metastasis. 25805931 2015
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma 		0.060 Biomarker disease BEFREE These findings provide insights into the clinical prospect of miR-1290-based therapies for non-small cell lung cancer. 25783528 2015
CUI: C0279626
Disease: Squamous cell carcinoma of esophagus
Squamous cell carcinoma of esophagus 		0.040 Biomarker disease BEFREE Our findings suggested that miR-1290 may play an oncogenic role in cellular processes of ESCC. 25805931 2015
CUI: C0279626
Disease: Squamous cell carcinoma of esophagus
Squamous cell carcinoma of esophagus 		0.040 Biomarker disease BEFREE By overexpressing or silencing miR-1290 in ESCC cells, we experimentally validated that miR-1290 directly binds to the 3'-UTR of the NFIX transcript and degrade the NFIX mRNA to regulate NFIX expression. 26653554 2015
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.020 Biomarker phenotype BEFREE MiR-1290 promotes cancer progression by targeting nuclear factor I/X(NFIX) in esophageal squamous cell carcinoma (ESCC). 26653554 2015
CUI: C0280324
Disease: Laryngeal Squamous Cell Carcinoma
Laryngeal Squamous Cell Carcinoma 		0.020 Biomarker disease BEFREE Taken together, we propose miR-1290 as the new oncomiR involved in LSCC pathogenesis. 26694163 2015
CUI: C0595989
Disease: Carcinoma of larynx
Carcinoma of larynx 		0.010 Biomarker disease BEFREE Global miRNA Expression Profiling Identifies miR-1290 as Novel Potential oncomiR in Laryngeal Carcinoma. 26694163 2015
CUI: C1328504
Disease: Hormone refractory prostate cancer
Hormone refractory prostate cancer 		0.010 Biomarker disease BEFREE Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. 25129854 2015
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.090 AlteredExpression group BEFREE High miR-1290 expression in serum and tissue was significantly associated with tumor aggressiveness and poor prognosis. 27502702 2016